Nanjing Leads Biolabs Co. Ltd. Class H (9887)
9887 · Health Care · 
China
Nanjing Leads Biolabs Co. Ltd. Class H (9887) is a company in the Health Care sector, based in China. The stock is held in 3 ETFs we track. Anyone holding one of these ETFs also owns a small indirect stake in Nanjing Leads Biolabs.
How many funds hold this stock?
Below-average ETF coverage: 3 of the 95 ETFs we cover hold Nanjing Leads Biolabs, spread across 2 indices. That puts the stock in more ETFs than 23.2 % of the 4,334 stocks we cover.
The line counts the funds we cover, not the market. Dashed: how many funds published a holdings list on that date.
What ETF is Nanjing Leads Biolabs in?
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| SPYI / SPSA | msci-acwi-imi | 0.00 % | €0.00 |
| IS3N | msci-em-imi | 0.00 % | €0.00 |
The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Nanjing Leads Biolabs as of the fund's latest holdings list.
How much Nanjing Leads Biolabs Co. Ltd. Class H overlaps with other holdings in a portfolio is shown by the What's Inside Your ETF Portfolio and the ETF overlap check.
Stocks with similar ETF exposure
Names that reach a portfolio through largely the same funds as Nanjing Leads Biolabs — the figure counts the ETFs holding both.
| Stock | Ticker | Shared ETFs | r |
|---|---|---|---|
| HUTCHMED (China) Limited | 13 | 3 | – |
| Ascletis Pharma Inc. | 1672 | 3 | – |
| Consun Pharmaceutical Group Ltd. | 1681 | 3 | – |
| AK Medical Holdings Ltd. | 1789 | 3 | – |
| Everest Medicines Ltd. | 1952 | 3 | – |
| Simcere Pharmaceutical Group Limited | 2096 | 3 | – |
| Lepu Biopharma Co. Ltd. Class H | 2157 | 3 | – |
| Yidu Tech Inc. | 2158 | 3 | – |
